Dr. Etminan is the CEO of Epilytics and along with expert epidemiologists including Dr. Mohammad Mansournia, a world renown authority in the area of causal inference, has created a boutique consulting group that appeals to a wide range of audience who need accurate and timely epidemiologic analysis of epidemiologic data.

Dr. Etminan is an epidemiologist with specialty in pharmacoepidemiology. He has 20 years of experience in epidemiologic and pharmacoepidemiologic research using Big Data. He has more than 200 publications in top tier journals including JAMA, BMJ, Lancet, Am J Epidemiology and International Journal of Epidemiology among others. His research has received more than 500,000 views in different clinical and method-based journals.

In particular, his study on the risk of gastrointestinal adverse events with GLP-1 agonists (drugs like Ozempic) has been one of the most viewed research Letters in the history of JAMA.

Dr. Etminan has consulted on a wide range of epidemiologic topics with both industry, academia, attorneys and health authorities. He and his team of experienced epidemiologists and analysts are ready to take on all types of epidemiology related projects from medical writing and systematic reviews to complex causal and prediction modelling.